Product InformationRegistration Status: Active
FAMOPSIN 40 TABLET 40mg is approved to be sold in Singapore with effective from 1991-06-04. It is marketed by GOLDPLUS UNIVERSAL PTE LTD, with the registration number of SIN05640P.
This product contains Famotidine 40mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by REMEDICA LTD in CYPRUS.
It is a has been granted the exemption for supply without a presciption if it met certain criteria.
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [PubChem]
For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
Mechanism of Action
Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.
- The bioavailability of oral doses is 40-45%.
* renal cl=250-450 mL/min
Intravenous, mouse: LD50 = 244.4mg/kg; Oral, mouse: LD50 = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.
(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide | 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide | 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine | Famotidina | Famotidinum | N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide | Famotidine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.